견적문의

SYDNEY--( / )--SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has partnered with researchers from Nepean Blue Mountains Local Health District’s (NBMLHD) Nepean Hospital in an exclusive agreement to commercialise a host gene expression biomarker test for respiratory viral illness. Expression of the patented biomarker, IFI27, as discovered by NBMLHD Drs Anthony Maclean, Benjamin Tang and colleagues, is strongly correlated with disease progression in Influenza[1] and COVID-19 patients[2]. The commercial assay will be positioned to support clinicians facing difficult triage or patient management decisions, supporting risk-based stratification of patients presenting with respiratory viral illness, including COVID-19.

“Host biomarkers are important indicators of a patient’s response to an infection,” said Professor Maclean, from the Nepean Hospital’s Intensive Care Unit. “Markers linked to viral specific immune responses, such as IFI27 - an interferon stimulating gene - are particularly informative. When they get switched on, it tells all the other immune cells to come and fight the virus. Levels of this specific marker, measured in the blood, have been shown to be directly correlated to progression of respiratory viral illness.”

The SpeeDx biomarker test utilises newly patented InSigniaTM technology that enhances the measurement of gene expression and is designed to run on standard laboratory equipment, allowing for expedited development and rapid adoption in high- and low-throughput hospital settings.

“The availability of a simple diagnostic test that can accurately differentiate viral from bacterial causes of pulmonary disease, using a single-gene host biomarker, would transform patient management,” said Dr. Charles Cartwright, SpeeDx VP of Scientific Affairs. “Coupled with a pathogen detection assay and other disease indicators, this test can not only stratify patients based on risk of adverse disease progression, changes in the level of biomarker over time can inform more accurate prognoses and guide ongoing patient management decisions.”

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see:

About Nepean Blue Mountains Local Health District

Nepean Blue Mountains Local Health District is well placed to draw on over 100 years of continuously caring for the community, conducting research and delivering innovation. The Nepean Hospital Intensive Care Unit is part of NBMLHD’s 5,700-strong staff. Being on the frontline of health means NBMLHD has a focus on practical solutions that deliver maximum impact to the health and wellbeing of patients and their families.

References

[1] Tang BM et al. Eur Respir J. 2017 Jun 15;49(6):1602098.

[2]

View source version on businesswire.com:SpeeDx Partners with Nepean Hospital to Commercialise Respiratory Virus Host Biomarker Assay

ZURICH--( / )--ABB has reached an agreement to divest to Hitachi, Ltd. (Hitachi) 코인발행 야잘알닷컴 its remaining 19.9 코인발행 percent equity stake in the Hitachi Energy joint venture that was formed from ABB’s Power Grids business in 2020, with Hitachi holding 한게임장기 ZURICH--(stake of 80.1 percent. Hitachi has exercised its call option that was agreed between the parties in December 2018.

The call option’s exercise value is $1.679 billion. The companies have 코인발행 필터링 agreed to settle remaining obligations relating to the original transaction, and ABB will continue to provide transition services to Hitachi Energy for them to fully separate from ABB’s systems. ABB does not expect to record any significant gain or loss as a result of the sale. ABB expects net positive cash inflows of approximately $1.425 billion upon closing of the 재동포커 부일카 sale. The transaction is subject to 코인발행 Txxx regulatory approvals and closing is 코인발행 미국메가밀리언 expected to happen in the fourth quarter 2022.

삼성선물 “We코인발행 캔디넷 are delighted to have agreed on the final part of the transaction earlier than 코인발행 꿈번호 expected and on favorable terms. This will further strengthen our balance sheet and give us additional flexibility in our capital allocation decisions,” said Timo 코인발행 호주복권 Ihamuotila, Chief Financial Officer of ABB.

ABB (ABBN: SIX Swiss Ex) is a leading 코인발행 데일리비디오 global technology company that energizes the 재동포커 연금복권520회 transformation of society and industry to achieve a more productive, sustainable future. By connecting software to its electrification, robotics, automation and motion portfolio, ABB pushes the boundaries of technology to 야동 ABBperformance to new levels. With a history of excellence stretching back more than 130 years, 코인발행 로또인쇄프로그램 ABB’s success is driven by about 105,000 talented employees in over 100 countries.

Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers‘ and society’s challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products, under the business structure of Digital Systems & Services, Green Energy & Mobility, Connective Industries and 코인발행 Automotive Systems. Driven by green, digital, and innovation, we aim for growth through collaboration with our customers. The company’s consolidated revenues for fiscal year 2021 (ended March 31, 2022) totaled 10,264.6 billion yen ($84,136 million USD), with 853 consolidated subsidiaries and approximately 370,000 employees worldwide. For more information on Hitachi, please visit the company's website 쩍벌댄스 Hitachi

Important notice 코인발행 밤열한시닷컴 재동포커 밤열한시닷컴 about forward-looking information 코인발행 로또액셀

This press release includes forward-looking information and statements which are based on current expectations, 코인발행 소라걸스 estimates and projections about the factors that may affect our future performance. These are generally identifiable by statements containing words such as “expects”, “estimates”, or similar expressions. However, there are many risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this press release. These include business risks associated with the volatile global economic environment and political conditions, costs associated with compliance activities, changes in governmental regulations and currency exchange rates and such other factors as may be discussed from time to time in ABB Ltd’s filings with the 코인발행 일일운세 U.S. Securities and Exchange Commission, including its Annual Reports on Form 20-F. Although ABB Ltd believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

View source version 재동포커 추천사이트 on businesswire.com:Korea Newswire 쩍벌댄스 Viewyour news 코인발행 로또4개 across every media channels through 코인발행 the industry’s largest press release distribution network